VA Research and Development LOGO

Logo for the Journal of Rehab R&D
Volume 42 Number 5, September/October 2005
Pages 625 — 634


Abstract - Effect of a vitamin D analog on leg bone mineral density in patients with chronic spinal cord injury

William A. Bauman, MD;1-4* Ann M. Spungen, EdD;1-2,4 Nancy Morrison, RN;1 Run-Lin Zhang, MD;1
Ernest Schwartz, MD1-2

1Department of Veterans Affairs (VA) Rehabilitation Research and Development Center of Excellence; 2Spinal Cord Damage Research Center; 3Medical, Spinal Cord Injury, and Research Services; VA Medical Center, Bronx, NY; 4Departments of Medicine and Rehabilitation Medicine, The Mount Sinai Medical Center, New York, NY
Abstract-A randomized, placebo-controlled trial was performed to determine the effect of a vitamin D analog (1-alpha-hydroxyvitamin D2 [1-alpha D2]) on the bone mineral density (BMD) in patients with chronic spinal cord injury (SCI). Forty subjects with chronic complete motor SCI were enrolled. The mean plus or minus standard deviation age and duration of injury were 42 plus or minus 12 yr and 11 plus or minus 10 yr, respectively. Either 4 micrograms 1-alpha D2 (n = 19) or placebo (n = 21) was administered daily for 24 mo. Metabolic markers of bone resorption and formation were obtained. Regional lower-limb dual-energy x-ray absorptiometry was performed at baseline and at 6, 12, 18, and 24 mo. Leg BMD and percent change from baseline significantly increased at 6 (percent change only), 12, 18, and 24 mo in the treatment group, but not in the placebo group. Urinary N-telopeptide, a marker of bone resorption, was significantly reduced during treatment with 1-alpha D2, but markers of bone formation were not changed.
Key words: 1-alpha-hydroxyvitamin D2, bone markers, bone metabolism in SCI, bone mineral density, cigarette smoking, disuse osteoporosis, Hectorol, N-telopeptide, paraplegia, spinal cord injury, tetraplegia, vitamin D analog.

 → go to Contents Page for Volume 42, No 4
 → go to HTML version of this article
 → go to PDF version of this article